Prevymis Европейски съюз - малтийски - EMA (European Medicines Agency)

prevymis

merck sharp & dohme b.v. - letermovir - infezzjonijiet taċ-ċitomegalovirus - antivirali għal użu sistemiku - prevymis huwa indikat għall-profilassi ta ' riattivazzjoni iċ-ċitomagalovirus (cmv) u l-marda f ' reċipjenti cmv-seroposittivi adulti [r +] tat-transplant taċ-ċelloli staminali haematopoietic ċelloli alloġeniċi (hsct). għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu adattat ta ' aġenti antivirali.

Nerlynx Европейски съюз - малтийски - EMA (European Medicines Agency)

nerlynx

pierre fabre medicament - neratinib - neoplażmi tas-sider - aġenti antineoplastiċi - nerlynx huwa indikat għall-estiż kura awżiljarja ta 'pazjenti adulti bil-istadju bikri pożittiv għar-riċetturi tal-ormon tat-her2-overexpressed/amplifikati-kanċer tas-sider u li huma anqas minn sena mill-tlestija ta'qabel l-adjuvant' trastuzumab terapija bbażata fuq.

Pifeltro Европейски съюз - малтийски - EMA (European Medicines Agency)

pifeltro

merck sharp & dohme b.v. - doravirine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.

Vocabria Европейски съюз - малтийски - EMA (European Medicines Agency)

vocabria

viiv healthcare b.v. - cabotegavir sodium, cabotegravir - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna.

Retsevmo Европейски съюз - малтийски - EMA (European Medicines Agency)

retsevmo

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - aġenti antineoplastiċi - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Livtencity Европейски съюз - малтийски - EMA (European Medicines Agency)

livtencity

takeda pharmaceuticals international ag ireland branch - maribavir - infezzjonijiet taċ-ċitomegalovirus - antivirali għal użu sistemiku - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu adattat ta ' aġenti antivirali.